The benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

Editor

7 years ago

Roy S. Herbst, MD, PhD, explains the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC at Annual Meeting 2018.